NasdaqGS - Nasdaq Real Time Price USD

ImmunityBio, Inc. (IBRX)

4.9750 +0.1550 (+3.22%)
As of 10:33 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
622.0000
622.0000
240.0000
934.0000
605.0000
Operating Expense
361,986.0000
361,986.0000
350,857.0000
331,214.0000
210,825.0000
Operating Income
-361,364.0000
-361,364.0000
-350,617.0000
-330,280.0000
-210,220.0000
Net Non Operating Interest Income Expense
-128,335.0000
-128,335.0000
-60,807.0000
-14,013.0000
-7,349.0000
Other Income Expense
-94,193.0000
-94,193.0000
-5,862.0000
-5,546.0000
-8,464.0000
Pretax Income
-583,892.0000
-583,892.0000
-417,286.0000
-349,839.0000
-226,033.0000
Tax Provision
-40.0000
-40.0000
34.0000
9.0000
-1,846.0000
Net Income Common Stockholders
-583,196.0000
-583,196.0000
-416,567.0000
-346,790.0000
-221,851.0000
Diluted NI Available to Com Stockholders
-583,196.0000
-583,196.0000
-416,567.0000
-346,790.0000
-221,851.0000
Basic EPS
-1.04
-1.15
-1.04
-0.89
-0.58
Diluted EPS
-1.04
-1.15
-1.04
-0.89
-0.58
Basic Average Shares
442,156.5960
508,635.5920
399,900.3740
389,234.1560
383,179.3760
Diluted Average Shares
442,156.5960
508,635.5920
399,900.3740
389,234.1560
383,179.3760
Total Operating Income as Reported
-362,250.0000
-362,250.0000
-351,298.0000
-330,280.0000
-220,880.0000
Total Expenses
361,986.0000
361,986.0000
350,857.0000
331,214.0000
210,825.0000
Net Income from Continuing & Discontinued Operation
-583,196.0000
-583,196.0000
-416,567.0000
-346,790.0000
-221,851.0000
Normalized Income
-533,137.4295
-533,137.4295
-423,255.9300
-343,542.9600
-212,831.7360
Interest Income
863.0000
863.0000
2,708.0000
836.0000
1,725.0000
Interest Expense
129,198.0000
129,198.0000
63,515.0000
14,849.0000
9,074.0000
Net Interest Income
-128,335.0000
-128,335.0000
-60,807.0000
-14,013.0000
-7,349.0000
EBIT
-454,694.0000
-454,694.0000
-353,771.0000
-334,990.0000
-216,959.0000
EBITDA
-436,182.0000
-436,182.0000
-335,511.0000
-320,752.0000
-204,220.0000
Reconciled Depreciation
18,512.0000
18,512.0000
18,260.0000
14,238.0000
12,739.0000
Net Income from Continuing Operation Net Minority Interest
-583,196.0000
-583,196.0000
-416,567.0000
-346,790.0000
-221,851.0000
Total Unusual Items Excluding Goodwill
-50,062.0000
-50,062.0000
8,467.0000
-4,448.0000
-9,092.0000
Total Unusual Items
-50,062.0000
-50,062.0000
8,467.0000
-4,448.0000
-9,092.0000
Normalized EBITDA
-386,120.0000
-386,120.0000
-343,978.0000
-316,304.0000
-195,128.0000
Tax Rate for Calcs
0.0000
0.0000
0.0002
0.0003
0.0000
Tax Effect of Unusual Items
-3.4295
-3.4295
1,778.0700
-1,200.9600
-72.7360
12/31/2020 - 7/28/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MLEC Moolec Science SA
1.3500
-7.53%
 
BPTH Bio-Path Holdings, Inc.
2.4500
-2.00%
 
NKGN NKGen Biotech, Inc.
1.9000
+11.05%
 
IOVA Iovance Biotherapeutics, Inc.
11.24
-4.01%
 
PALI Palisade Bio, Inc.
5.90
-7.09%
 
ABEO Abeona Therapeutics Inc.
3.1800
+0.32%
 
DAWN Day One Biopharmaceuticals, Inc.
13.58
-10.60%
 
VNDA Vanda Pharmaceuticals Inc.
4.5400
-0.44%
 
VKTX Viking Therapeutics, Inc.
66.09
+1.57%
 
ABVC ABVC BioPharma, Inc.
1.4399
-2.71%